Chronoscale Holdings Corp quarterly report, Q3 FY2025

Business Context and Reporting Period

Company: Ekso Bionics Holdings, Inc. (Note: Input metadata referenced "Chronoscale Corp," but the filing text identifies the registrant as Ekso Bionics Holdings, Inc., trading as EKSO).

Reporting Period: Quarterly Report on Form 10-Q for the period ended September 30, 2025.

Business Overview: The Company designs, develops, and markets exoskeleton products for healthcare (neurorehabilitation and mobility) and industrial applications. Key products include the EksoNR, Ekso Indego Therapy, and Ekso Indego Personal. The Company operates as a single segment and is currently exploring strategic transactions, including potential acquisitions or the sale of its business.

Key Financial Metrics

Metric Three Months Ended Sept 30, 2025 Nine Months Ended Sept 30, 2025 Sept 30, 2025 Balance Sheet
Revenue $4.23 million $9.66 million N/A
Gross Profit $2.55 million $5.17 million N/A
Gross Margin 60% 54% N/A
Net Loss $(1.42) million $(7.02) million N/A
Loss Per Share (Basic/Diluted) $(0.54) $(3.35) N/A
Cash and Restricted Cash N/A N/A $2.72 million
Total Debt (Current + Non-Current) N/A N/A $4.26 million
Working Capital N/A N/A $5.86 million

Note: Debt includes $1.94 million convertible promissory note, $1.25 million current notes payable, and $1.07 million non-current notes payable.

Material Changes vs. Prior Period

  • Revenue:
    • Q3 2025 vs. Q3 2024: Increased 2% ($0.1M) driven by higher Enterprise Health device sales in the Americas, partially offset by declines in EMEA.
    • YTD 2025 vs. YTD 2024: Decreased 25% ($3.2M) primarily due to lower Enterprise Health device sales in EMEA, partially offset by growth in Americas Enterprise and Personal Health sales.
  • Operating Expenses:
    • Q3 2025: Total operating expenses decreased 19% ($0.9M) year-over-year due to lower payroll expenses (aided by Employee Retention Credit receipts) and reduced headcount.
    • YTD 2025: Total operating expenses decreased 7% ($1.0M) year-over-year. General and Administrative expenses increased 5% due to higher legal and audit costs, offset by savings in other areas.
  • Other Income/Expense:
    • YTD 2025: Significant unrealized gain on foreign exchange of $2.0 million (vs. $0.2 million in 2024) due to currency revaluations of inter-company assets/liabilities.
    • Q3 2025: Unrealized foreign exchange gain was de minimis compared to $0.6 million in Q3 2024.
  • Debt Structure:
    • On September 12, 2025, the Company paid off a $2.0 million secured term loan with Banc of California using restricted cash.
    • Simultaneously, the Company entered into a new $2.0 million Secured Promissory Note with B. Riley Commercial Capital, LLC, bearing 10% interest plus a 10% exit fee.

Guidance, Outlook, Risks, and Unusual Items

  • Going Concern Warning: Management has concluded that substantial doubt exists regarding the Company's ability to continue as a going concern for 12 months from the issuance date. Cash on hand ($2.72 million) is estimated to fund operations only into the first quarter of 2026. The Company is actively seeking additional financing.
  • Strategic Transactions: The Company is exploring one or more strategic transactions, which could include the acquisition of a business in a different industry or the sale of all or substantially all of its current business. No timetable has been set.
  • Reimbursement Outlook: The Company is ramping up sales of the Ekso Indego Personal device following CMS Medicare reimbursement approval. Management expects Personal Health revenue to contribute more quarter-over-quarter, though Enterprise Health remains the primary revenue source for 2025.
  • Unusual Items:
    • Intangible Asset Impairment: Recorded a $0.18 million impairment loss on intellectual property related to a terminated license agreement with Vanderbilt University.
    • Employee Retention Credit (ERC): Received $0.52 million in ERCs in August 2025, recorded as an offset to operating expenses and interest income.
  • Risk Factors:
    • Dependence on third-party payor reimbursement policies (CMS, Medicaid, private insurers).
    • Potential impact of federal funding cuts and government shutdowns on regulatory approvals and customer purchasing power.
    • Supply chain disruptions and tariff risks affecting manufacturing costs.

Investor Verification Checklist

  • Liquidity Runway: Verify the status of ongoing financing efforts, as the Company explicitly states it cannot fund operations beyond Q1 2026 without new capital.
  • Debt Covenants: Review the terms of the new B. Riley Promissory Note, specifically the "Qualified Financing" trigger for maturity and the 10% exit fee obligation.
  • Revenue Concentration: Note that one customer accounted for 41% of revenue in Q3 2025 and 29% of accounts receivable as of Sept 30, 2025.
  • Strategic Review: Monitor for updates on the exploration of strategic transactions (sale or acquisition), which could fundamentally alter the business model.
  • Reimbursement Execution: Track the volume of successful CMS reimbursement claims for the Ekso Indego Personal device to validate the growth thesis for the Personal Health market.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.